Biotech News

Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use

**Eli Lilly’s Alzheimer’s Drug Donanemab Rejected for NHS Use** Eli Lilly’s promising Alzheimer’s treatment, donanemab, has hit a roadblock with the UK’s National Health Service (NHS), which recently chose not to recommend its use. This decision places donanemab in an uncertain position within the UK healthcare system, despite its potential…

Read More
Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use

Scroll to Top